AFT Pharmaceuticals Limited (AFT.NZ)
NZD 2.8
(0.0%)
NZD 2.8
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 24.23 Million NZD | 29.79% |
| 2023 | 18.67 Million NZD | -6.99% |
| 2022 | 20.07 Million NZD | 77.22% |
| 2021 | 11.32 Million NZD | -45.87% |
| 2020 | 20.92 Million NZD | 239.87% |
| 2019 | 6.15 Million NZD | 161.49% |
| 2018 | -10.01 Million NZD | 30.71% |
| 2017 | -14.45 Million NZD | -38.44% |
| 2016 | -10.43 Million NZD | -75.01% |
| 2015 | -5.96 Million NZD | -285.83% |
| 2014 | 3.21 Million NZD | 14.07% |
| 2013 | 2.81 Million NZD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.62 Million NZD | -89.98% |
| 2024 Q2 | 3.16 Million NZD | 94.77% |
| 2024 Q4 | 10.49 Million NZD | 0.0% |
| 2024 Q3 | 10.49 Million NZD | 231.52% |
| 2024 FY | 23.7 Million NZD | 26.97% |
| 2023 Q3 | 8.1 Million NZD | 134.48% |
| 2023 Q2 | 3.45 Million NZD | 100.0% |
| 2023 FY | 18.67 Million NZD | -6.99% |
| 2023 Q4 | 16.21 Million NZD | 100.0% |
| 2023 Q1 | 1.72 Million NZD | -88.32% |
| 2022 Q1 | 2.74 Million NZD | -65.2% |
| 2022 FY | 20.07 Million NZD | 77.22% |
| 2022 Q4 | 14.79 Million NZD | 98.63% |
| 2022 Q3 | 7.44 Million NZD | 38.77% |
| 2022 Q2 | 5.36 Million NZD | 95.52% |
| 2021 Q2 | 2.19 Million NZD | 81.01% |
| 2021 Q3 | 4.14 Million NZD | 89.01% |
| 2021 Q4 | 7.89 Million NZD | 90.44% |
| 2021 FY | 11.32 Million NZD | -45.87% |
| 2021 Q1 | 1.21 Million NZD | -83.45% |
| 2020 Q1 | 1.14 Million NZD | -64.28% |
| 2020 Q2 | 3.65 Million NZD | 219.28% |
| 2020 Q4 | 7.31 Million NZD | 58.78% |
| 2020 Q3 | 4.6 Million NZD | 26.2% |
| 2020 FY | 20.92 Million NZD | 239.87% |
| 2019 Q1 | 117.5 Thousand NZD | 109.06% |
| 2019 FY | 6.15 Million NZD | 161.49% |
| 2019 Q4 | 3.2 Million NZD | 0.0% |
| 2019 Q3 | 3.2 Million NZD | 2624.26% |
| 2019 Q2 | 117.5 Thousand NZD | 0.0% |
| 2018 FY | -10.01 Million NZD | 30.71% |
| 2018 Q2 | -3.02 Million NZD | 0.0% |
| 2018 Q3 | -1.29 Million NZD | 57.15% |
| 2018 Q4 | -1.29 Million NZD | 0.0% |
| 2018 Q1 | -3.02 Million NZD | 10.01% |
| 2017 Q1 | -4.1 Million NZD | 63.64% |
| 2017 Q3 | -3.36 Million NZD | 18.09% |
| 2017 FY | -14.45 Million NZD | -38.44% |
| 2017 Q4 | -3.36 Million NZD | 0.0% |
| 2017 Q2 | -4.1 Million NZD | 0.0% |
| 2016 Q2 | -1.76 Million NZD | 0.0% |
| 2016 FY | -10.43 Million NZD | -75.01% |
| 2016 Q4 | -11.29 Million NZD | -339.9% |
| 2016 Q3 | -2.56 Million NZD | -45.7% |
| 2016 Q1 | -1.76 Million NZD | -123.12% |
| 2015 Q4 | -789.5 Thousand NZD | 0.0% |
| 2015 Q2 | -2.19 Million NZD | 0.0% |
| 2015 FY | -5.96 Million NZD | -285.83% |
| 2015 Q3 | -789.5 Thousand NZD | 64.0% |
| 2015 Q1 | -2.19 Million NZD | 0.0% |
| 2014 FY | 3.21 Million NZD | 14.07% |
| 2013 FY | 2.81 Million NZD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Greenfern Industries Limited | -1.45 Million NZD | 1768.693% |
| Rua Bioscience Limited | -4.84 Million NZD | 600.709% |